UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
Potential Treatment For Damage Done To Heart Cells During And After Heart Attack
Date: Feb-11-2013Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks. The compounds also protect against additional injury from restored blood flow after an attack, a process known as reperfusion...
Treating Cancers, Neurological Disorders, And Infectious Diseases Using Unique Peptide
Date: Feb-11-2013UT Southwestern Medical Center scientists have synthesized a peptide that shows potential for pharmaceutical development into agents for treating infections, neurodegenerative disorders, and cancer through an ability to induce a cell-recycling process called autophagy. Autophagy is a fundamental recycling process in which intracellular enzymes digest unneeded and broken parts of the cell into their individual building blocks, which are then reassembled into new parts. The role of autophagy is crucial both in keeping cells healthy and in enabling them to fight different diseases...
Device That Can Create 3-D Images Of Living Cells And Track Their Reaction To Various Stimuli Without The Use Of Contrast Dyes Or Fluorophores
Date: Feb-11-2013In the world of microscopy, this advance is almost comparable to the leap from photography to live television. Two young EPFL researchers, Yann Cotte and Fatih Toy, have designed a device that combines holographic microscopy and computational image processing to observe living biological tissues at the nanoscale. Their research is being done under the supervision of Christian Depeursinge, head of the Microvision and Microdiagnostics Group in EPFL's School of Engineering...
Using MicroRNA To Identify Triple-Negative Breast Cancer Subtypes
Date: Feb-11-2013A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy. The findings, by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) working with collaborators in Italy, could lead to new screening methods, prognostic markers and perhaps new targeted treatments for this aggressive and often-fatal form of breast cancer. The study is published in the journal PLoS ONE...
Obese Women Taking Certain Contraceptive May Be At Increased Risk For Type 2 Diabetes
Date: Feb-11-2013A first-of-its-kind study by researchers at the Keck School of Medicine of the University of Southern California (USC) indicates that healthy, obese, reproductive-age women who use long-acting reversible contraception (LARC) containing the hormone progestin have a slightly increased risk for developing type 2 diabetes when compared to those who use non-hormonal contraception. The research concludes that progestin-releasing LARC appears to be safe for use by such women but needs further investigation. Nicole M...
Valentine Doubts Reflect A More Serious Disorder, Relationship OCD
Date: Feb-11-2013This Valentine's Day, longing hearts everywhere will eagerly anticipate a romantic gift or gesture from their partner. For millions, however, Valentine's is the worst day, despite good relationships, leaving them confused and conflicted, guilty or mistrustful, due to "Relationship OCD" or "ROCD." ROCD is a form of OCD in which the sufferer has irrational doubts of their partner's love, and goes to extreme lengths to compulsively check up on them. They constantly call them, or inspect their call or email history. Valentines is one of many tests of their partner's love...
Boosting Body's Natural Tumor-Fighting Protein May Aid Cancer Treatment
Date: Feb-11-2013New research from the US suggests it may be possible boost a natural tumor-fighting protein that is already present in the body's immune system to enhance the effectiveness of cancer treatment, especially for advanced cancers that are difficult to treat. The researchers, led by Penn State Hershey Cancer Institute and College of Medicine, report their findings in the 6 February online issue of Science Translational Medicine. New treatments are needed for advanced cancer, as estimates suggest more than half a million Americans will die of cancer in 2013...
For Kidney Disease Patients, Frequent Treatments Improve Health But Increase Risks For Certain Complications
Date: Feb-11-2013Compared with standard dialysis, frequent dialysis can cause complications related to repeated access to the blood, requiring patients to undergo more repair procedures to the site through which blood is removed and returned, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The study provides important information for physicians and patients as they weigh different dialysis options. Frequent hemodialysis requires accessing the blood more often than conventional hemodialysis...
Humans Included In Most Comprehensive Tree Of Life To Date
Date: Feb-11-2013An international team of scientists including University of Florida researchers has generated the most comprehensive tree of life to date on placental mammals, which are those bearing live young, including bats, rodents, whales and humans. Appearing in the journal Science, the study details how researchers used both genetic and physical traits to reconstruct the common ancestor of placental mammals, the creature that gave rise to many mammals alive today. The data show that contrary to a commonly held theory, the group diversified after the extinction of dinosaurs 65 million years ago...
Pomalyst (pomalidomide) For Advanced Multiple Myeloma Approved By FDA
Date: Feb-11-2013Pomalyst (pomalidomide) has been approved by the FDA for the treatment of patients with multiple myeloma whose cancer progressed after being treated with other medications. Pomalyst, which is presented in capsule form, modulates the immune system so that the patient's own body destroys cancerous cells and undermines their growth. Pomalidomide is aimed at multiple myeloma patients who had been administered at least two previous therapies which did not stop the progression of the disease within two months (relapsed and refractory), including therapies with bortezomib and lenalidomide...
Stay Connected
